FDA modernization policy issues; General issues related to rare disease and clinical trials; General issues related to diagnostics for patients with rare diseases; Issues related to drug pricing; Issues related to reform of pharmacy benefit managers; Issues related to trade; Issues related to Newborn Screening and Genetic Testing;
Source-reported fields
Filing overview
- Type
- Registration
- Posted
- Jun 30, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- STANTON PARK GROUP
- Client
- KYOWA KIRIN
- Filing UUID
- d4b3502a-85a6-42a8-857b-4e03d8177c00
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
FDA modernization policy issues; General issues related to rare disease and clinical trials; General issues related to diagnostics for patients with rare diseases; Issues related to drug pricing; Issues related to reform of pharmacy benefit managers; Issues related to trade; Issues related to Newborn Screening and Genetic Testing;
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.